News

The effort will combine the unprecedented genomic and clinical data from the MMRF’s landmark CoMMpass Study with revolutionary GNS machine learning platforms and rapid computer simulations. The work

In 2013, Ferrer successfully completed a first phase III clinical trial of Ozenoxacin in adult and paediatric patients aged two years and older with impetigo. The study demonstrated

The agreement, which was established in February 2013 and due to expire on December 31, 2015, will now extend to December 31, 2019. Moreover, the payment structure of

The goal of the research collaboration with 23andMe is to study circadian clock genes and ultimately improve therapeutic development for diseases related to molecular clocks. Research into the

Targin is a fixed combination of prolonged-release oxycodone/naloxone, which is the first opioid which has been granted a licence in the EU to treat RLS. According to the

Aptiom is approved for use as adjunctive treatment of partial-onset seizures and is not approved for use as monotherapy for partial-onset seizures. The sNDA included data from two

Top-line data from the immediate post-vaccination observation period of the trial will be reported in late second quarter of 2015. More than 300 patients from 17 institutions in

With these collaborations, Novartis will now have access to new CRISPR technology platforms for the discovery and development of new medicines. A clustered regularly interspaced short palindromic repeats

The Phase II trial is designed to evaluate the safety, efficacy and tolerability of KD025, the company’s orally bioavailable, potent and highly selective inhibitor of Rho-associated coiled-coiled kinase